Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA HCC-206: Pumitamig alone or with Ipilimumab in First-Line Advanced HCC
NCT07291076Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Primary completion
- Oct 2029
- Countries
- 14
01
Overview
A Phase 2 trial of pumitamig in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Mar 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07291076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291076.